{"id":"W4405230305","doi":"10.1093/cid/ciae596","title":"Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)","year":2024,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"Respiratory viral infections research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca Pharma Poland; Sanofi; Sanofi Australia; AstraZeneca","keywords":"Medicine; Placebo; Respiratory tract infections; Respiratory system; Pneumovirus; Respiratory tract; Immunization; Randomized controlled trial; Monoclonal antibody; Paramyxoviridae; Virology; Lower respiratory tract infection; Immunology; Internal medicine; Virus; Antibody; Viral disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00433264,0.001576284,0.003327315,0.0004246722,0.0004356634,0.001301807,0.001019272,0.001550951,0.00617034],"category_scores_gemma":[0.002939362,0.0006522373,0.003144974,0.0003910625,0.001039511,0.001160344,0.0004308895,0.002524731,0.0007514191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008358394,"about_ca_system_score_gemma":0.001158965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005334879,"about_ca_topic_score_gemma":0.001457538,"domain_scores_codex":[0.9985595,0.0009085576,0.00009255231,0.0001773318,0.0001023571,0.0001595754],"domain_scores_gemma":[0.9983479,0.000630512,0.0004287222,0.0001398927,0.0001170881,0.0003359714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.98318,0.0041298,0.0005672339,0.0005906017,0.001375774,0.00002956603,0.00004228346,0.00019936,0.002077885,0.0000493285,0.0003367688,0.007421311],"study_design_scores_gemma":[0.9028634,0.09255888,0.002538501,0.00004344181,0.0008767286,0.00003150017,0.00002178895,0.0003276758,0.000311212,0.000087744,0.0003248526,0.00001418965],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9863579,0.005519942,0.0006890344,0.0005130281,0.0003649724,0.004259315,0.000972683,0.00008383516,0.001239331],"genre_scores_gemma":[0.9869131,0.002796309,0.001249767,0.0007485192,0.0003823149,0.005386692,0.0008029658,0.00002259709,0.001697633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00617034,"threshold_uncertainty_score":0.02291352,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1157906588258769,"score_gpt":0.5118620954638883,"score_spread":0.3960714366380114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}